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Myeloid-derived suppressor cells (MDSCs) are 
one of the major components of the immune-
suppressive network responsible for T cell de-
fects in cancer. These cells also contribute to 
tumor progression via regulation of angiogen-
esis and tumor cell motility. MDSC is a large 
group of myeloid cells consisting of immature 
macrophages (M), granulocytes, and DCs, as 
well as myeloid cells at earlier stages of differen-
tiation (Sica and Bronte, 2007; Talmadge, 2007; 
Gabrilovich and Nagaraj, 2009; Peranzoni et al., 
2010). In mice, MDSCs express both the my-
eloid lineage differentiation antigen Gr-1 (Ly6G 
and Ly6C) and M integrin CD11b. Two major 
groups of MDSCs are now identified: cells 
with granulocytic (CD11b+Ly6G+Ly6Clow) and 
monocytic  (CD11b+Ly6GLy6Chigh)  pheno-
type (Movahedi et al., 2008; Youn et al., 2008). 
In  humans,  MDSCs  are  generally  defined  as 
cells that express CD11b, the common myeloid 
marker CD33, but lack the expression of mark-
ers of mature myeloid and lymphoid cells and 
the MHC class II molecule HLA-DR (Almand 
et al., 2001; Zea et al., 2005; Diaz-Montero et al., 
2009; Nagaraj et al., 2010). In tumor-free mice, 
MDSCs represent 30% of the normal BM cells 
and <3% of all nucleated splenocytes. In tumor-
bearing mice, this population undergoes dra-
matic expansion. In many tumor models the 
proportion of MDSC represents >20% of all 
splenocytes, and MDSCs are easily detectable in 
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Myeloid-derived suppressor cells (MDSCs) are a major component of the immune- 
suppressive network described in cancer and many other pathological conditions. We  
demonstrate that although MDSCs from peripheral lymphoid organs and the tumor site 
share similar phenotype and morphology, these cells display profound functional differ-
ences. MDSC from peripheral lymphoid organs suppressed antigen-specific CD8+ T cells but 
failed to inhibit nonspecific T cell function. In sharp contrast, tumor MDSC suppressed both 
antigen-specific and nonspecific T cell activity. The tumor microenvironment caused rapid 
and dramatic up-regulation of arginase I and inducible nitric oxide synthase in MDSC, 
which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphate–
oxidase and reactive oxygen species in these cells. In contrast to MDSC from the spleen, 
MDSC from the tumor site rapidly differentiated into macrophages. Exposure of spleen 
MDSC to hypoxia resulted in the conversion of these cells to nonspecific suppressors and 
their preferential differentiation to macrophages. Hypoxia-inducible factor (HIF) 1 was 
found to be primarily responsible for the observed effects of the tumor microenvironment 
on MDSC differentiation and function. Thus, hypoxia via HIF-1 dramatically alters the 
function of MDSC in the tumor microenvironment and redirects their differentiation toward 
tumor-associated macrophages, hence providing a mechanistic link between different 
myeloid suppressive cells in the tumor microenvironment.
© 2010 Corzo et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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In this study, we addressed this issue by investigating the 
function and differentiation of MDSC at the tumor site using 
an experimental model where tumors were generated as asci-
tes. This allowed for a rapid isolation of cells and enabled di-
rect experiments with adoptive transfer of MDSC directly into 
the tumor microenvironment. In this paper, we report that 
MDSCs in tumor-bearing mice display a biological dichotomy 
regulated by the tumor microenvironment. In peripheral lym-
phoid organs, MDSC primarily caused antigen-specific T cell 
nonresponsiveness, which was mediated by ROS. In contrast, 
within tumor microenvironment, MDSC with the same phe-
notype and morphology had low ROS levels but dramatically 
up-regulated  NO  production  and  arginase  activity,  which 
caused suppression of antigen-nonspecific T cell functions.   
In contrast to MDSC from the spleen, MDSC in the tumor 
microenvironment rapidly differentiated primarily into TAM. 
This process was mediated primarily by hypoxia via hypoxia-
inducible factor (HIF) 1. Our data thus help to explain the 
differences in the nature of T cell suppression between tumor 
and peripheral lymphoid organs in tumor-bearing hosts and 
suggest a regulatory pathway of myeloid cell function in the 
tumor microenvironment.
RESULTS
Phenotype and function of MDSC in the tumor site
To directly compare MDSC from the tumor site to MDSC 
from peripheral lymphoid organs (spleen), we have developed 
a model where EL-4 tumor grows as an ascites in C57BL/6 
mice. The dose of EL-4 cells was selected to form an ascites 
within  3  wk  after  tumor  injection.  MDSCs  in  mice  are 
broadly defined as Gr-1+CD11b+ cells. These markers were 
used to sort MDSC from within the spleen and tumor of the 
same mouse (Fig. 1 A). MDSC from both sites expressed the same 
level of Gr-1 and CD11b molecules and had similar mixed gran-
ulocytic and monocytic cell morphology (Fig. 1 B). Granulo-
cytic MDSCs (CD11b+Ly6G+Ly6Clow) were a predominant type 
of MDSC in both sites. There was no difference between the 
ratio of granulocytic and monocytic (CD11b+Ly6GLy6Chigh) 
MDSC isolated from tumor or spleens (Fig. 1 C). The CD11c 
marker specific for DCs was not expressed on either spleen or 
tumor MDSC, and <10% of MDSC expressed the CD115 or 
F4/80 markers of monocytes/macrophages (Fig. 1 C). Thus, 
MDSC from the tumor and spleen in this tumor model had 
similar morphology and phenotype.
To  investigate  whether  these  findings  are  confined  to 
only an ascites model, we compared the phenotype of MDSC 
isolated from spleens and solid tumors in several models. EL-4 
thymoma and B16.F10 melanoma were established as sub-
cutaneous tumors, CC10 was a lung tumor spontaneously 
developed in transgenic mice. The mCC10TAg transgene 
was made by fusing the coding sequences of the SV40 TAg 
gene with the mCC10 promoter (Magdaleno et al., 1997). 
This  promoter  targets  transgene  expression  specifically  to 
proximal pulmonary lung epithelial Clara cells. These mice 
develop multifocal pulmonary adenocarcinoma in the lung at 
3 mo of age. In all three models, tumor tissues and spleens 
tumors and lymph nodes (Kusmartsev and Gabrilovich, 2006; 
Rabinovich et al., 2007; Sica and Bronte, 2007; Gabrilovich   
and Nagaraj, 2009). Similar expansion, albeit to a lesser degree,   
is observed in patients with cancer. In the presence of ap-
propriate cytokines in vitro and after adoptive transfer in vivo,   
MDSC can differentiate into mature myeloid cells (Kusmartsev 
and Gabrilovich, 2003). This differentiation is blocked, how-
ever, in the presence of tumor cell–conditioned media or in 
tumor-bearing hosts (Kusmartsev and Gabrilovich, 2003; 
Talmadge, 2007).
Extensive studies in recent years suggested several mecha-
nisms of MDSC-mediated immune suppression that involve 
arginine (Bronte and Zanovello, 2005; Rodríguez and Ochoa, 
2008) and cysteine (Srivastava et al., 2010) metabolism, expres-
sion of some surface molecules (Pan et al., 2010), up-regulation 
of reactive oxygen species (ROS), and production of different 
cytokines (Talmadge, 2007; Gabrilovich and Nagaraj, 2009). 
Practically all these studies were performed with MDSC isolated 
from peripheral lymphoid organs (mostly spleen).
Although an important role of MDSC in tumor-associated 
immune suppression is well established in recent years, its nature 
remains unclear. One of the major unresolved questions is 
the role of MDSCs in peripheral lymphoid organs and tumor 
tissues as well as their relationship with M and DCs. The 
main paradox is that, despite the presence of a large number 
of MDSCs in spleens and lymph nodes of tumor-bearing 
mice and in the peripheral blood of cancer patients with ad-
vanced disease, T cells mostly retain the ability to respond to 
different tumor-nonspecific stimuli including viruses, lectins, 
costimulatory molecules, IL-2, and stimulation with CD3- 
and CD28-specific antibodies (Fricke et al., 2007; Monu and 
Frey, 2007; Nagaraj et al., 2007). In a sharp contrast, T cells 
directly isolated from tumors display profound defects in their 
ability to respond to those stimuli (Rabinowich et al., 1996; 
Lopez et al., 1998; Reichert et al., 2002). Some evidence 
may suggest that MDSC-mediated immune suppression in 
peripheral lymphoid organs could be mainly tumor antigen 
specific. MDSCs mediate antigen-specific T cell tolerance by 
taking up soluble antigens, including tumor-associated anti-
gens, processing them, and presenting them to CD8+ T cells 
in the context of MHC class I (Kusmartsev et al., 2005;   
Movahedi et al., 2008).
The role of tumor-associated MDSC remains largely ob-
scure. Despite the fact that the cells with the phenotype of 
MDSC are abundantly present in tumor tissues but are often 
referred to as monocytes, M, or granulocytes, the relation-
ship (or lack thereof) between MDSC and tumor-associated 
macrophages (TAMs) is unclear. This confusion is derived 
from the difficulties in clearly defining the phenotype of my-
eloid cells in the tumor site. This creates a convoluted, rather 
incoherent picture of the various functions of different my-
eloid cell subsets within the tumor. Ambiguity of the biologi-
cal role of and the relationship between different myeloid cell 
populations within the tumor site severely limits our under-
standing of the biology of tumor progression and the devel-
opment of targeted therapeutics.JEM VOL. 207, October 25, 2010 
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of suppression was significantly (P < 0.05) higher in tumor 
MDSC (Fig. 1 E). However, the major differences were ob-
served during the analysis of T cell response to nonspecific 
stimuli. Spleen MDSC did not suppress nonspecific T cell 
responses. In contrast, tumor MDSC exerted a profound sup-
pressive effect (Fig. 1 F).
To  evaluate  MDSC  function  in  the  CC10  transgenic 
model of lung cancer, MDSCs were isolated from tumor or 
spleens of the 3-mo-old mice and then added to responder 
cells from naive mice stimulated with anti-CD3/CD28 anti-
bodies. Tumor MDSC showed a marked suppressive activity, 
whereas spleen MDSC failed to suppress nonspecific T cell 
proliferation (Fig. S1 A). To assess antigen-specific T cell re-
sponses, we used OT-1 transgenic T cells expressing TCR 
specific for the OVA-derived epitope SIINFEKL. Tumor 
MDSC suppressed T cell proliferation in response to specific 
peptide at ratios as low as 1:8 (Fig. S1 B).
Our data show that MDSCs from the tumor site and 
spleen of the same mouse differ profoundly in the ability to 
suppress T cell function. Several factors have been previously 
implicated in suppressive activity mediated by MDSC. They 
include ROS, arginase, inducible nitric oxide synthase (iNOS), 
were digested and the phenotype of MDSC was compared 
side by side. Tumor and spleen MDSC displayed a similar 
phenotype in all models. The proportion of F4/80+ cells was 
slightly  higher  in  tumor-associated  MDSC  than  in  spleen 
MDSC. However, the differences were not statistically sig-
nificant (P > 0.05; Fig. 1 D).
We compared the ability of tumor and spleen MDSC to 
suppress antigen-specific and -nonspecific T cell responses. 
Two basic functions of T cells were evaluated: IFN- pro-
duction  and  T  cell  proliferation.  The  antigen-specific  re-
sponse to MHC class I–restricted SIYRYYGL (SIY) peptide 
was measured in 2C transgenic CD8+ T cells. The antigen-
nonspecific T cell response was evaluated after stimulation 
with  anti-CD3/CD28  antibodies.  MDSCs  were  isolated 
from the ascites and spleens of the same mice and were used 
under the same experimental conditions. Gr-1+CD11b+ im-
mature myeloid cells (IMCs) from spleens of naive tumor-
free mice were used as a control. As was demonstrated in 
previous  studies,  IMCs  lack  immunosuppressive  activity 
(Kusmartsev et al., 2004, 2005; Zhou et al., 2007; Yamamoto 
et al., 2008). Both spleen and tumor MDSCs effectively sup-
pressed the antigen-specific T cell response, although the level 
Figure 1.  Phenotype and function of MDSC in 
tumor site. (A and B) 3 × 105 EL-4 tumor cells were 
injected i.p. into C57BL/6 mice. After 3 wk, spleens and 
cells from tumor ascites were collected. Gr-1+CD11b+ 
MDSC were sorted (A) and their morphology was eval-
uated by staining with H&E (B; 200× magnification). 
Bars, 10 µm. (C, left) Surface markers in gated  
Gr-1+  CD11b+ MDSC isolated from spleens and tumors of 
the same mice. (C, right) Ratio of granulocytic/mono-
cytic MDSC. Five experiments were performed. Error 
bars show mean and SD. (D) Surface markers in gated 
Gr-1+CD11b+ MDSC isolated from spleens and solid 
tumors of the same mice. All tissues were subjected to 
the same enzymatic digestions. Three indicated tumor 
models were used. Each experiment included four mice. 
Mean ± SD is shown. (E and F) Gr-1+CD11b+ cells puri-
fied from spleens of tumor-free mice (naive) or spleens 
(SPL) and ascites (ASC) of EL-4 tumor-bearing mice 
were cultured at indicated ratios with 105 splenocytes 
from transgenic 2C mice. (E) Splenocytes were stimu-
lated with control and specific peptides. IFN- produc-
tion was measured in quadruplicates in ELISPOT assay. 
Number of spots per 105 2C splenocytes is shown. 
Values in cells stimulated with control peptide were 
subtracted. *, statistically significant (P < 0.05) differ-
ence from naive mice. A typical example of four inde-
pendent experiments is shown. (F) Splenocytes were 
stimulated with anti-CD3/CD28 antibodies. In addition 
to the measurement of IFN- production, evaluation 
of splenocyte proliferation was performed using  
3H-thymidine uptake. CPM, counts per minute. Thymi-
dine uptake in cells stimulated with control peptide was 
<1,000 cpm. All experiments were performed in tripli-
cates. A typical result of three performed experiments 
is shown. Error bars show mean and SD. *, statistically 
significant (P < 0.05) differences from naive mice.2442 Hypoxia maintains MDSC in tumor microenvironment | Corzo et al.
significantly lower in MDSC from the tumor than that in 
MDSC from the spleen (Fig. 2 B).
In contrast, MDSC isolated from the tumor site had a much 
higher level of inos expression and NO production, as well as 
arginase-1 expression and arginase activity, than did spleen 
MDSC from the same mice (Fig. 2, C and D). To identify the 
link between MDSC suppressive activity and ROS, we per-
formed experiments with gp91phox/ tumor-bearing mice. 
MDSCs from these mice do not produce ROS (Corzo et al., 
2009). Lack of ROS did not affect the suppressive potential 
of tumor MDSC but completely eliminated the suppressive 
and NO (Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg 
and Sinha, 2009). We evaluated ROS levels within the pop-
ulation of MDSC from spleen and tumors. IMCs from spleen 
of naive mice served as controls. As expected, MDSC from 
spleens of tumor-bearing mice displayed a significantly higher 
level of ROS than the cells from tumor-free mice. Surpris-
ingly, ROS production in tumor MDSC was significantly 
lower than that of spleen MDSC (Fig. 2 A). Expression of   
gp91phox and p47phox components of the nicotinamide adenine 
dinucleotide phosphate–oxidase (NOX) complex responsible 
for ROS production in MDSC (Corzo et al., 2009) was   
Figure 2.  Factors regulating MDSC suppressive activity. (A) Cells collected from the tumor site or spleens of EL-4 tumor-bearing mice were stimu-
lated with PMA, labeled with 1 µM dichlorodihydrofluorescein diacetate (DCFDA), and stained with APC-conjugated anti–Gr-1 antibody and PerCP- 
conjugated anti-CD11b antibody. DCFDA fluorescence was measured in Gr-1+CD11b+ population by flow cytometry. Cumulative results from four independently 
performed experiments are shown. In all panels, * denotes statistically significant difference (P < 0.05) from naive mice. (B) RNA was extracted from  
Gr-1+CD11b+ cells isolated from spleens or tumor of the same mice and expression of gp91phox and p47phox was measured in quantitative real-time PCR 
(qRT-PCR). The experiment was performed in triplicates and repeated twice with the same result. (C) MDSCs from spleen and tumor ascites were stimulated 
with 30 ng/ml IFN- for 48 h and expression of inos was measured in qRT-PCR (left). The same cells were mixed at the indicated ratio with 2 × 105 sple-
nocytes stimulated with anti-CD3/CD28 antibodies. After a 48-h incubation, culture medium was collected and assayed for nitrites (right). Experiments 
were performed in triplicates and repeated three times with the same results. #, statistically significant (P < 0.05) differences between MDSC isolated 
from spleen and tumor at the same time point. (D) Arginase 1 gene expression (left) and enzymatic activity (right) were evaluated in MDSC from tumor 
site and spleen. All experiments were performed in triplicates and repeated three times with the same results. *, statistically significant differences  
(P < 0.05) from naive mice; #, statistically significant (P < 0.05) differences between ascites and spleen of the same mice. (E) Suppressive activity of MDSC 
from gp91phox knockout mice on IFN- production by transgenic 2C T cells after stimulation with either specific peptide (left) or anti-CD3/CD28 antibodies 
(right). Each experiment was performed in triplicates. Two experiments with the same results were performed. *, statistically significant differences  
(P < 0.05) from naive mice. (F) MDSCs isolated from spleens or tumor site were incubated at a 1:4 ratio with naive syngeneic splenocytes stimulated with anti-
CD3/CD28 antibodies in the presence of iNOS (0.5 mM L-NNMA) and arginase (0.5 mM nor-NOHA) inhibitors. IFN- production was measured in ELISPOT 
assay and cell proliferation by incorporation of 3H-thymidine. Three experiments with the same results were performed. Error bars show mean and SD.JEM VOL. 207, October 25, 2010 
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In contrast, iNOS levels in tumor MDSC were substantially 
higher than in blood MDSC (Fig. 3 C). To evaluate func-
tional activity, MDSCs were sorted from peripheral blood 
and tumor tissues. To account for the possible effect of en-
zymes used for tissue digestion on MDSC function, periph-
eral blood was treated the same way as tumor tissues. MDSCs 
were then added to patients’ mononuclear cells, and T cell 
proliferation in response to PHA was measured. MDSC isolated 
from peripheral blood did not affect PHA-inducible T cell 
proliferation, whereas MDSC from tumor tissues significantly 
(P = 0.0008) decreased it (Fig. 3 D). Thus, these results, 
which are similar to those observed in tumor-bearing mice, 
suggest that differences in MDSC function may represent   
a general phenomenon.
Effect of the tumor microenvironment on MDSC function 
and differentiation
MDSCs are a heterogeneous group of cells. Therefore, de-
spite similarities in the morphology and phenotype of MDSC 
isolated from tumor sites and spleens, it is difficult to formally 
exclude the possibility that MDSC in different sites may rep-
resent different populations of myeloid cells. To address this 
question, as well as to identify the mechanisms of MDSC 
function in the tumor site, we used a direct transfer of   
Gr-1+CD11b+ MDSC isolated from spleens of EL-4 tumor-
bearing congenic (CD45.1+) mice into the ascites of EL-4 
tumor-bearing  C57BL/6  (CD45.2+)  recipients.  EL-4  cells 
expressed the CD45.2 but not the CD45.1 marker (unpub-
lished data). This allowed for discrimination between tumor 
activity of spleen MDSC (Fig. 2 E). Inhibition of iNOS with 
LMMA and of arginase I with nor-NOH completely abro-
gated suppressive activity of tumor-derived MDSC (Fig. 2 F). 
Thus, MDSCs from the tumor use primarily arginase and 
NO to suppress T cell function, whereas splenic MDSCs use 
primarily ROS.
We asked whether up-regulation of iNOS and down-
regulation  of  ROS  also  occurred  in  MDSC  from  solid   
tumors. To address this question we used s.c. EL-4 tumors. 
Amounts of iNOS and ROS level were measured within the   
Gr-1+CD11b+ population of tumor and spleen MDSC using 
flow cytometry immediately after enzymatic digestion of tis-
sues. Tumor MDSC displayed substantially higher levels of 
iNOS than did spleen MDSC (Fig. S2). Conversely, the level 
of ROS, as well as the expression of p47phox and gp91phox sub-
units of NOX, in tumor MDSC was substantially lower than 
in spleen MDSC (Fig. S3).
Our data indicate that MDSC from the tumor site and 
peripheral lymphoid organs of tumor-bearing mice differ in 
their ability to produce ROS and NO. To test whether a 
similar phenomenon is observed in cancer patients, we studied 
paired samples of peripheral blood and tumor tissues obtained 
from patients with head and neck cancer (HNC). MDSCs 
were defined as CD14CD11b+CD33+ cells (Fig. 3 A). Previ-
ous studies have shown that these cells have the functional 
characteristics of MDSC (Zea et al., 2005; Nagaraj et al., 
2010). ROS and iNOS were measured in MDSC using flow 
cytometry. MDSC in the tumor had significantly lower ROS 
production than did MDSC in peripheral blood (Fig. 3 B).   
Figure 3.  MDSC in peripheral blood and tumor tissues of cancer patients. (A–C) Peripheral blood and tumor tissues were collected from patients 
with HNC during surgical resection. Single cell suspensions were prepared as described in Materials and methods and cells were stained with anti-CD11b, 
anti-CD14, and anti-CD33 antibodies. (A) A typical example of gating of CD11b+CD14CD33+ MDSC from the same patient in flow cytometry. (B) Cells 
were stained with DCFDA to detect ROS level within the population of CD11b+CD14CD33+ cells from the same patient. Cumulative results from six pa-
tients are shown. **, statistically significant difference between MDSC in the tumor site and peripheral blood (P = 0.007). MFI, mean fluorescence intensity. 
(C) Cells were labeled with anti-iNOS antibody and the protein level was measured within the population of CD11b+CD14CD33+ cells. Cumulative results 
from six patients are shown. *, statistically significant difference between MDSC in the tumor site and peripheral blood (P = 0.04). (D) Proliferation of 
PHA-stimulated mononuclear cells in the presence of MDSC isolated from tumor and peripheral blood of the same patient. PBMCs (105/well) were stimu-
lated with 5 µg/ml PHA in the presence of indicated amount of MDSC. Proliferation was measured in triplicate on day 3 by uptake of 3H-thymidine. 
Proliferation of PBMC in the absence of MDSC was considered 100%. ***, statistically significant difference between groups (P = 0.0008). Samples from 
three patients were tested and cumulative results are shown. Error bars show mean and SD.2444 Hypoxia maintains MDSC in tumor microenvironment | Corzo et al.
Expression of arg1 and inos was significantly higher, whereas 
expression of p47phox was significantly lower, in donor cells 
isolated from tumor than in those from spleens (Fig. 4 C). 
Dramatic suppressive activity, as well as high levels of arg1 
and  inos  and  down-regulation  of  ROS,  was  observed  in   
donor cells isolated from tumor sites 18 h after the transfer 
(Fig. S4). Thus, substantial changes in MDSC suppressive activ-
ity and up-regulation of inos and arg1 were observed as early as 
4 h after adoptive transfer of MDSC into the tumor site.
cells and MDSC. In parallel, MDSCs were injected i.v. into 
either EL-4 tumor-bearing or tumor-free recipients to evalu-
ate donor cells in the spleen. Donor cells isolated from spleens 
4 h after the transfer significantly (P < 0.01) suppressed anti-
gen-specific T cell responses (Fig. 4 A). However, these cells 
failed to inhibit the nonspecific T cell response (Fig. 4 B). 
In contrast, donor cells isolated from tumor site 4 h after the 
transfer exhibited strong suppressive activity of both antigen-
specific -and nonspecific T cell functions (Fig. 4, A and B). 
Figure 4.  Effect of the tumor microenvironment on MDSC function and differentiation. MDSC isolated from spleens of congenic CD45.1+ mice 
bearing 3 wk s.c. EL-4 tumors were transferred into ascites of CD45.2+ EL-4 tumor-bearing recipients. CD45.1+ donor cells were recovered using magnetic 
beads 4 h after cell transfer. For controls, CD45.1+ MDSC were transferred i.v. into EL-4 tumor-bearing recipients or naive recipients and recovered from 
spleens 4 h after cell transfer. (A) After adoptive transfer, CD45.1+ MDSCs were cultured with 2C spleen responder cells (Resp.; 1:4 ratio) stimulated with 
control and specific peptides. IFN- production was measured by ELISPOT assay. The number of spots per 105 splenocytes is shown. Values in cells stimu-
lated with control peptide were subtracted. Each experiment was performed in triplicates and repeated twice. *, statistically significant differences (P < 0.05) 
from the values in splenocytes cultured alone. Error bars show mean and SD. (B) Similar experiments performed using stimulation with anti-CD3/CD28 
antibodies. Error bars show mean and SD. (C) Evaluation of gene expression of argI, iNOS, and p47phox in MDSC postadoptive transfer. Each experiment was 
performed in triplicates and repeated twice with the same results. Error bars show mean and SD. (D and E) Differentiation of MDSC at different time points 
after transfer. *, statistically significant (P < 0.05) differences between spleens and ascites. (D) The percentage of Gr-1+CD11b+ MDSC among all CD45.1+ 
donor cells. Before, the phenotype of MDSC before transfer to the mice. Error bars show mean and SD. (E) The percentage of mature macrophages  
(F4/80+CD11b+Gr-1) and DCs (CD11c+CD11b+Gr-1) among CD45.1+ donor cells. Mean ± SD from three experiments is shown. In D and E, * denotes  
statistically significant (P < 0.05) differences between the proportion of cells in spleens and tumors at the same time point. (F) Differentiation of MDSC in 
tumor-free peritoneum. Congenic CD45.1+ mice were injected i.p. with 1 ml thioglycollate. 3 d later, 5 × 106 MDSCs isolated from spleen of EL-4 tumor-
bearing C57BL/6 (CD45.2+) mice were injected i.p. Cells were collected 18 h after the injection and the proportion of different myeloid cells was measured 
within the gated population of CD45.2+ donor cells by flow cytometry. Two independent experiments were performed. Error bars show mean and SD.JEM VOL. 207, October 25, 2010 
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tumor-bearing mice were incubated in complete culture me-
dium and GM-CSF at normoxic or hypoxic (1% O2) condi-
tions for 48 h. Hypoxia significantly (P < 0.05) reduced 
the expression of gp91phox and p47phox components of NOX 
(Fig. 5 A), which resulted in a substantial decrease in the level 
of ROS production in these cells (Fig. 5 B). In contrast, hy-
poxia dramatically up-regulated expression of arg1 and inos 
(Fig. 5 C). MDSC cultured in hypoxia acquired the ability to 
suppress T cell proliferation and IFN- production in re-
sponse  to  nonspecific  stimuli  (anti-CD3/CD28  antibody; 
Fig. 5 D). This effect was independent of the presence of 
tumor cell–conditioned medium in the culture (Fig. 5 E). 
Thus, hypoxia recapitulated the effect of the tumor microen-
vironment on MDSC function.
To assess the effect of hypoxia on mouse MDSC differen-
tiation, Gr-1+CD11b+ cells from spleens of tumor-bearing 
mice were cultured for 5 d in normoxia or hypoxia in the pres-
ence of GM-CSF. Hypoxia caused accumulation of cells with 
macrophage morphology (Fig. 5 F). After a 5-d culture under 
hypoxic conditions, the proportion of Gr-1+CD11b+ MDSC 
was fourfold lower compared with cells cultured at normoxia 
(P < 0.01), whereas the proportion of Gr-1CD11b+F4/80+ 
M was significantly higher (P < 0.05; Fig. 5 G and Fig. S6). 
In contrast, the proportion of CD11c+ cells was signifi-
cantly (P < 0.05) higher among the cells cultured at nor-
moxia than those incubated at hypoxia (Fig. 5 G). In addition, 
the majority of cells that differentiated from MDSC under 
hypoxia were positive for nonspecific esterase, the enzyme 
specific for monocytes/M (Fig. 5 H). Thus, these data 
indicate that hypoxia promoted differentiation of MDSC to 
M, which is similar to the effect observed in the tumor 
microenvironment.
Using  the  hypoxia-sensitive  compound  pimonidazole, 
we evaluated distribution of F4/80+ and Gr-1+ cells in more 
and less hypoxic areas of solid s.c. EL-4 tumor. More hypoxic 
areas of tumors contained significantly higher numbers of 
F4/80+ M than less hypoxic areas (P < 0.05; Fig. 5, I and J). 
These results are consistent with previously reported observa-
tions about accumulation of TAM in hypoxic areas of tumor 
(Lewis and Murdoch, 2005; Movahedi et al., 2010). In con-
trast, the number of Gr-1+ cells in these areas was not differ-
ent (Fig. 5, I and J).
We then asked whether hypoxia could cause functional 
polarization of M cells during their differentiation from 
MDSC. MDSCs isolated from spleens of tumor-bearing mice 
were cultured at normoxia and hypoxia for 5 d, followed by 
isolation of F4/80+ cells and evaluation of their cytokine 
gene expression. As controls, we used F4/80+ M obtained 
from peritoneal cavities on naive mice and F4/80+ cells col-
lected from the ascites of tumor-bearing mice. As expected, 
TAM expressed substantially higher levels of arg1 and il-10 
than control peritoneal M (Fig. S7). M generated from 
MDSC under normoxic conditions expressed inos and il-6 
but no or very little il-12, il-10, or arg1. In contrast, M 
generated under hypoxic conditions expressed substantially 
higher levels of il-10, arg1, iNOS, il-12, and il-6 (Fig. S7).
It is known that MDSC can differentiate into mature 
myeloid cells. We therefore investigated the fate of these cells 
after transfer into the tumor site. CD45.1+ MDSCs isolated 
from spleens of tumor-bearing mice were transferred i.v. or 
injected directly into ascites of CD45.2+ recipients. No differ-
ences were observed in the phenotype of cells isolated 4 h after 
the transfer (unpublished data). 18 h after the transfer, most 
of the donor MDSC (>70%) in the spleen and tumor site 
still retained the MDSC phenotype (Gr-1+CD11b+; Fig. 4 D 
and Fig. S4). Those donor cells that lost Gr-1 expression 
were represented in the spleens evenly by CD11c+ DCs and 
CD11b+F4/80+ M (Fig. 4 E). In sharp contrast, most of 
the Gr-1 donor cells in tumor site were CD11b+F4/80+ 
M (Fig. 4 E and Fig. S5). After 48 h, the proportion of 
Gr-1+CD11b+ MDSC among donor cells in spleens remained 
about the same (>60%). However, in the tumor site it was 
substantially decreased to <30% of all donor cells (Fig. 4 D). 
After 48 h, practically all Gr-1 donor cells in the tumor site, 
but only 30% of cells in the spleen, were F4/80+CD11b+ 
M. In contrast, few Gr-1 cells in the tumor site express the 
CD11c marker of DCs, whereas in spleen >30% of these cells 
were CD11c+ (Fig. 4 E). 3 d after the transfer, all Gr-1 donor 
cells in the tumor site remained F4/80+CD11b+ M, whereas 
M represented <20% of these cells in spleen (Fig. 4 E).
Because tumors in this model were established in perito-
neum, we investigated the possible effect of a tumor-free 
peritoneum microenvironment on MDSC differentiation 
using CD45.1+ congeneic recipients. To retain MDSC in 
peritoneum cavity, thioglycollate was injected i.p. 3 d before 
injection of MDSC. Donor cells rapidly migrated out from 
peritoneum  cavity  even  in  the  presence  of  thioglycollate; 
therefore, the analysis was possible only during the first 48 h 
after the transfer. The proportion of donor cells retaining 
MDSC phonotype (Gr-1+CD11b+) 2 d after the transfer was 
60%, which was substantially higher than the proportion of 
these cells in tumor site (Fig. 4, D and F). CD11b+F4/80+ 
M represented <50% of Gr-1 donor cells 48 h after the 
transfer of MDSC. This was substantially lower than the   
proportion of these cells found in tumor (Fig. 4, E and F). 
Thus, the pattern of MDSC differentiation in peritoneum in   
tumor-free mice was very different from that observed in the 
ascites of tumor-bearing mice. It suggests that the effect of 
tumor ascites on MDSC differentiation was mediated pri-
marily by tumor itself rather than peritoneum microenviron-
ment. Thus, in the tumor microenvironment, MDSC rapidly 
differentiated into F4/80+CD11b+ M. In contrast, MDSC 
in spleens remained undifferentiated much longer and differ-
entiated equally to M and DCs.
Regulation of MDSC function by hypoxia
Our  data  demonstrates  that  the  tumor  microenvironment 
rapidly changes the function of MDSCs and promotes their 
differentiation to TAM. We investigated the possible mecha-
nism of this effect. Hypoxia is one of the major characteristics 
of the tumor microenvironment. Therefore, we tested the 
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factor on MDSC function, we used deferoxamine (DFO), 
which stabilizes HIF-1 and serves as an HIF-1 mimetic. 
Spleen MDSCs from tumor-bearing mice were treated with 
DFO for 48 h, washed, and then added to splenocytes stimu-
lated with anti-CD3/CD28 antibodies. Nontreated MDSC 
did not suppress nonspecific T cell proliferation (Fig. 6 B) or 
HIF-1 regulates MDSC differentiation and function
Up-regulation of HIF-1 is one of the major effects of hypoxia. 
We investigated the possible role of HIF-1 in the regulation of 
MDSC differentiation and function. A 4-h incubation of spleen 
MDSC under hypoxia resulted in substantial up-regulation of 
HIF-1 (Fig. 6 A). To test the possible role of this transcription 
Figure 5.  Regulation of MDSC function 
by hypoxia. MDSCs were isolated from 
spleens of CT26 tumor-bearing mice and cul-
tured in medium containing 10 ng/ml GM-CSF 
and 25% CT26 tumor cell conditioned me-
dium (TCCM) under normoxic and hypoxic 
(1% O2) conditions using a hypoxic chamber. 
(A) Expression of NOX subunits was evaluated 
in triplicates after 2 d of culture using qRT-
PCR. Results are shown as mean ± SD from 
three experiments performed with similar 
results. *, statistically significant (P < 0.05) 
differences between normoxia and hypoxia 
groups. (B) Cells were collected after 3 d of 
culture, loaded with DCFDA, and labeled with 
anti–Gr-1 and anti–CD11b antibodies. Fluor-
escence intensity of DCFDA was measured 
within the Gr-1+CD11b+ population. A typical 
result of three independently performed ex-
periments is shown. (C) Expression of argI and 
inos was evaluated in triplicates in MDSC 
after 24- and 48-h incubations in hypoxic and 
normoxic conditions using qRT-PCR. Results 
from three independently performed experi-
ments are shown. *, statistically significant  
(P < 0.05) differences between normoxia and 
hypoxia groups. (D) MDSCs were cultured for 
48 h under normoxic or hypoxic conditions 
and their ability to suppress proliferation of 
anti-CD3/CD28–stimulated splenocytes was 
evaluated. Cell proliferation was measured in 
triplicates by 3H-thymidine uptake. A typical 
result from two performed experiments is 
shown. (E) BM cells were cultured for 3 d in 
media containing 10 ng/ml GM-CSF and 25% 
TCCM. After that time, cells were incubated 
under normoxic or hypoxic conditions for an 
additional 2 d. Gr-1+ cells were isolated and 
cultured with splenocytes from BALB/c mice 
stimulated with anti-CD3/CD28 antibodies. 
Production of IFN- was measured in tripli-
cates by ELISPOT assay. *, statistically signifi-
cant (P < 0.05) differences from values of 
splenocytes cultured alone. Two independent 
experiments were performed. (F) MDSCs were 
cultured for 5 d with 10 ng/ml GM-CSF and 
25% TCCM in normoxia or hypoxia and then fixed and stained with H&E (400× magnification). Bars, 10 µm. A typical example of two independently per-
formed experiments is shown. (G) Phenotype of MDSC cultured for 5 d in hypoxia or normoxia. The proportions of cells with indicated phenotype were 
evaluated by flow cytometry. Cumulative results of four performed experiments are shown. *, statistical significant differences (P < 0.05) between the 
groups. Error bars in A, C–E, and G show mean and SD. (H) Cells derived from a 5-d culture of MDSC in hypoxia were tested for nonspecific esterase activ-
ity. Assay was repeated using cells isolated from two independent experiments. Bars, 10 µm. (I and J) An association between the presence of M and 
MDSC in hypoxic areas of the tumor. (I) Number of Gr-1+ or F4/80+ cells per one 800-µm-×-600-µm field. A total of 8–16 fields was counted for each 
area and results are shown as mean ± SD. *, statistically significant (P < 0.05) differences between areas with less and more hypoxia. (J) Representative 
areas of s.c. EL-4 tumors are shown. Brown, staining with antibody detecting area of hypoxia; red; F4/80+ or Gr-1+ cells. Bars, 100 µm.JEM VOL. 207, October 25, 2010 
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from HIF-1–deficient and WT mice showed similar en-
graftment potential (Fig. 6 H). 2 wk after BM transfer, mice 
were inoculated s.c. with EL-4 tumor cells. No significant 
differences in tumor growth between the groups were seen 
(unpublished data). Populations of myeloid cells were evaluated 
when the tumor reached 1.5 cm in diameter (3 wk after tumor 
injection). Gr-1+CD11b+ MDSC were expanded in spleens of 
tumor-bearing mice. To assess the effect of the tumor microen-
vironment on HIF-1–deficient MDSC, Gr-1+CD11b+ cells 
were isolated from spleens of tumor-bearing mice reconsti-
tuted with HIF-1–deficient or WT BM and then injected 
directly into the ascites of CD45.1+ congenic mice. 12 h 
later, Gr-1+CD45.2+ donor MDSCs were isolated and used 
in experiments. MDSC with WT HIF-1 showed profound 
suppressive activity against T cells stimulated with anti-CD3/
CD28 antibodies (Fig. 6 J). Expression of arg1 and inos in 
HIF-1–positive MDSC was dramatically up-regulated after 
transfer into the tumor site (Fig. 6 I). The suppressive effect 
of HIF-1–deficient MDSC, as well as the expression of arg1 
and inos in these cells, was significantly (P < 0.01) lower (Fig. 6, 
I and J). Precisely the opposite effect was observed in the levels 
IFN- production (Fig. 6 C). However, MDSC pretreated 
with DFO caused profound suppression of T cell function 
(Fig. 6, B and C). DFO caused significant up-regulation of 
the expression of arg1 and inos and a decrease in the expres-
sion of NOX components p47phox and gp91phox (Fig. 6, D and E). 
It also promoted M differentiation from MDSC during a 
5-d culture with GM-CSF (Fig. 6 F). Collectively, these re-
sults were very similar to the effect of hypoxia on MDSC and 
suggested that HIF-1 could be responsible for the observed 
effect of the tumor microenvironment on these cells.
To directly test this possibility, we used mice with condi-
tional HIF-1 deletion. HIF-1 flox mice were crossed with 
Mx-Cre mice and HIF-1 deletion was induced by repeated 
poly:IC administration (Fig. 6 G). Poly:IC is a strong inducer 
of type I IFN and so would dramatically affect MDSC func-
tion. Therefore, to exclude this possibility and to make sure 
that HIF-1 deletion is confined only to hematopoietic cells, 
we used BM reconstitution of WT recipients. BM cells from 
CD45.2+  HIF-1–deficient  (HIF-1floxCre+/)  or  control 
(HIF-1floxCre/) mice were used to reconstitute lethally 
irradiated CD45.1+ congeneic naive mice. BM progenitors 
Figure 6.  HIF-1 regulation of MDSC function.  
(A) MDSCs isolated from spleens of EL-4 tumor-bearing mice 
were cultured with 10 ng/ml GM-CSF in hypoxia for 4 or 16 h. 
The level of HIF1- was measured by Western blotting. A typical 
example of three independently performed experiments is 
shown. (B–F) MDSCs were treated with various concentrations 
of HIF-1 stabilizer DFO in the presence of 10 ng/ml GM-CSF 
for 48 h and then washed and used in the experiments. No 
effect of DFO on MDSC cell viability was observed (not de-
picted). Each experiment was performed in triplicates and re-
peated two times with the same result. Results are shown as 
mean ± SD. (B and C) Effect of MDSC on proliferation (B) and 
IFN- production (C) of splenocytes stimulated with anti-CD3/
CD28 antibodies. (D and E) Effect of a 48-h treatment of MDSC 
with DFO on the expression of arg1, inos, gp91phox, and p47phox. 
Each experiment was performed in triplicates. Three experi-
ments were performed with the same result. (F) Percentage of 
F4/80+CD11b+ M differentiated from MDSC treated with DFO 
for 5 d. Cumulative results (mean ± SD) of three experiments 
are shown. In D and F, * denotes statistically significant (P < 0.05) 
differences from untreated (0 µM) samples. (G) Evaluation  
of BM reconstitution by BM cells from HIF-1–deficient 
mice. Expression is shown of hif-1 in HIF-1fl/flCre+/ and  
HIF-1fl/flCre/ mice after treatment with poly I:C using real-
time PCR. Experiments were performed in triplicates in three 
mice. Error bars show mean and SD. (H) Reconstitution of  
lethally irradiated CD45.1+ congenic mice with CD45.2+ BM from 
HIF-1–deficient (HIF-1flox/flox, Cre+/) or WT (HIF-1 flox/flox, 
Cre/) mice. Blood of mice 2 wk after BM transfer was tested. 
A typical example of three experiments is shown. (I–K) CD45.1+ lethally irradiated recipients were reconstituted with BM cells from HIF-1 knockout (KO) or WT 
CD45.2+ mice. 2 wk later, mice were inoculated s.c. with 5 × 105 EL-4 tumor cells. 3 wk after that, CD45.2+ HIF-1 WT or KO MDSC were isolated from spleens of 
tumor-bearing mice and then transferred into ascites of congenic CD45.1+ mice. 12 h later, CD45.2+ CD11b+ donor cells were isolated and used in the subse-
quent experiments. (I) The MDSCs were cultured with anti-CD3/CD28 antibody-activated T cells (Resp., responder cells) and their proliferation was measured by 
3H-thymidine incorporation. Experiments were performed in triplicates. Mean ± SD is shown. Experiments were performed twice with the same result. (J) Ex-
pression of arg1 and inos was analyzed in the MDSC before and after adoptive transfer into the tumor milieu. Two independent experiments were performed in 
triplicates. In J and K, * denotes statistically significant (P < 0.05) differences between the groups. Error bars show mean and SD. (K) ROS level in MDSC after the 
adoptive transfer was determined with DCFDA. Cumulative results of two experiments are shown. Error bars show mean and SD.2448 Hypoxia maintains MDSC in tumor microenvironment | Corzo et al.
To verify the potential contribution of HIF-1 to the   
effect  of  hypoxia  on  MDSC,  HIF-1–deficient  and  WT 
MDSCs from spleens of tumor-bearing mice were cultured 
with GM-CSF for 5 d under hypoxic conditions. Hypoxia 
caused a dramatic up-regulation of arg1 and inos in HIF-1 
WT MDSC, whereas a much smaller effect was observed   
in HIF-1-deficient MDSC (Fig. 7 B). Lack of HIF-1  
decreased the viability of cells. After a 5-d culture of MDSC, 
the number of recovered HIF-1–deficient cells was three 
times smaller than the number of HIF-1+/+ cells. The pro-
portion of cells that retained the MDSC phenotype among   
HIF-1/ cells was slightly higher than among HIF-1+/+ 
cells (Fig. 7 C). Consistent with our data described in Fig. 5, 
the vast  majority  of  HIF-1  WT  MDSC  differentiated 
into Gr-1CD11b+F4/80 M. In striking contrast, only a 
small proportion of HIF-1–deficient MDSC differenti-
ated into M (Fig. 7 C).
Next, we studied the possible effect of HIF-1 on antitu-
mor responses. BM cells from HIF-1 KO or WT mice were 
transferred into lethally irradiated recipients, and 2 wk after 
the transfer mice were injected s.c. with B16.F10 tumor cells. 
When tumor became palpable (6 d after tumor inoculation), 
mice were injected with T cells from Pmel-1 transgenic mice. 
of ROS. HIF-1–deficient MDSCs had substantially higher 
ROS production than their WT counterparts (Fig. 6 K).
In separate experiments, we evaluated the phenotype of 
donor  cells  in  the  tumor  microenvironment  by  gating 
CD45.1+CD11b+ cells. The gating of CD11b+ cells was nec-
essary to exclude CD45.2 EL-4 tumor cells from the analysis. 
Before transfer, the purity of Gr-1+CD11b+ cells was >95%. 
Within 24 h after the transfer of either WT or HIF-1– 
deficient MDSC, 70% of donor (CD45.2+CD11b+) cells 
lost the expression of Gr-1 (unpublished data). Half of HIF-1 
WT Gr-1 donor cells acquired the F4/80 marker of M 
and 20% became CD11c+ DCs (Fig. 7 A). These results were 
similar to those described in Fig. 4 E demonstrating preferen-
tial differentiation of MDSC to M in tumor microenviron-
ment. In contrast, HIF-1–deficient MDSC acquired CD11c 
marker, with only 20% of cells expressing F4/80 (Fig. 7 A). 
As a result, the proportion of M differentiated in tumor site 
from HIF-1 WT MDSC was more than twofold higher 
than the proportion of cells differentiated from HIF-1– 
deficient MDSC (P < 0.05). Conversely, the proportion of 
CD11c+ DCs differentiated from HIF-1 WT MDSC was 
more than threefold lower than that from HIF-1 KO MDSC 
(P < 0.01; Fig. 7 A).
Figure 7.  Changes in MDSC function and differentiation induced by the tumor-microenvironment require HIF-1. (A) Percentage of M and DCs in 
the population of CD11b+Gr-1CD45.2+ donor cells 18 h after the adoptive transfer of HIF-1+/+ and HIF-1/ MDSC into ascites tumors of congeneic recipi-
ents. Each experiment included two mice per group and was performed twice. *, statistically significant (P < 0.05) differences between groups. (B and C) HIF-1–
deficient and WT MDSCs were generated in vivo by transfer of BM cells into tumor-bearing recipients as described in A. MDSCs were isolated and cultured with 
GM-CSF for 5 d under hypoxic or normoxic conditions. Error bars show mean and SD. (B) Expression of arg1 and inos was measured in triplicates in RT-PCR. Two 
independent experiments with the same results were performed. Error bars show mean and SD. (C) The phenotype of cells differentiated from MDSC after a 5-d 
culture with GM-CSF. Two independent experiments with the same results were performed. (D) Tumor growth of lethally irradiated mice reconstituted with either 
WT or HIV-1–deficient BM. Tumor was established by s.c. inoculation of 3 × 105 B16.F10 tumor cells 2 wk after transfer of BM to lethally irradiated recipients. 
Two groups of mice (control) were left untreated. Mice from two other groups received 3 × 106 splenocytes from Pmel-1 T cell receptor transgenic mice on day 6 
after tumor inoculation. 1 d later, the mice were immunized with specific peptide. Tumor growth was monitored every 3–4 d in individually tagged mice by mea-
suring two opposing diameters with a set of calipers. Each group included four to five mice. Results of individual mice are shown.JEM VOL. 207, October 25, 2010 
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spleens,  granulocytic  CD11b+Ly6G+Ly6Clow  MDSCs  pro-
duce a substantially higher level of ROS and a lower level of 
NO than monocytic CD11b+Ly6GLy6Chigh cells (Youn   
et al., 2008). It was possible that the composition of these 
MDSC  subsets  could  be  different  in  spleens  and  tumors, 
which would explain the differences in functional activity of 
MDSC. However, the results of the experiments argue against 
this explanation.
Thus,  this  study  demonstrated  a  dual  role  played  by 
MDSC in immune suppression in cancer depending on their 
location. This may contribute to the phenomenon described 
previously in tumor-bearing mice. Although T cells from pe-
ripheral lymphoid organs of these mice did not respond to 
tumor-associated antigen, they nevertheless retained the abil-
ity to respond to nonspecific stimuli (Radoja et al., 2000; 
Yang and Lattime, 2003). Recent years have provided ample 
evidence supporting an important role of ROS in spleen 
MDSC-mediated suppression of T cells (Sinha et al., 2005; 
Kusmartsev et al., 2008; Markiewski et al., 2008; Youn et al., 
2008; Mougiakakos et al., 2009). ROS was specifically impli-
cated in antigen-specific T cell tolerance mediated by MDSC 
(Nagaraj et al., 2007; Hardy et al., 2008).
However, a very different situation is observed with T cells 
isolated directly from tumors. Tumor-infiltrating lympho-
cytes displayed a profound defect in their function that could 
be overcome only after culture of these cells in the presence 
of antigen-presenting cells and IL-2. One possible explana-
tion of these differences could be that the tumor microenvi-
ronment  contains  a  large  number  of  different  suppressive 
factors that are not present in spleens. Our data demonstrate 
that the tumor microenvironment can convert MDSCs into 
nonspecific suppressor cells by up-regulating proteins involved 
in the metabolism of L-arginine. These enzymes (iNOS and 
arginase I) are known to be actively involved in T cell sup-
pression (Bronte and Zanovello, 2005; Rodríguez and Ochoa, 
2008). Importantly, they do not require antigen-specific con-
tact between MDSC and T cells to inhibit their function.
Up-regulation of arg1 and inos by MDSC in the tumor 
site is a very rapid process and takes only several hours to occur. 
One of the major factors that distinguish the tumor microen-
vironment from lymphoid organs is hypoxia. It appears that 
hypoxia plays a critical role in the regulation of MDSC func-
tion by the tumor microenvironment. Our experiments have 
demonstrated  that  exposure  of  spleen  MDSC  to  hypoxia 
could reproduce the effect of the tumor microenvironment 
on these cells by inducing a dramatic up-regulation of iNOS 
and arg-I, decreasing the expression of NOX2 and ROS and 
converting MDSC from antigen-specific to -nonspecific sup-
pressors. How can hypoxia affect the function of MDSC? The 
major molecular mechanism of the hypoxia effect is mediated 
by  the  HIF-1  transcription  factor.  In  hematopoietic  cells, 
HIF-1 is the predominant oxygen-sensitive subunit (Simon 
et al., 2002). Regulation of HIF-1 activity is mediated by 
posttranslational modification of the oxygen-dependent deg-
radation (ODD) domain of HIF-1. At oxygen levels >5%, 
hydroxylation of the proline residues 402 and 564 in the 
CD8+ T cells from these mice express TCR that recognizes 
Db-restricted epitope corresponding to amino acid positions 
25–33 of gp100 expressed in B16.F10 melanoma (Overwijk 
et al., 2003). Mice were immunized with specific peptide the 
next day. The control group included mice that did not re-
ceive T cells and immunization. This design allowed us to 
evaluate the antitumor effect of HIF-1 WT antigen-specific 
T cells in the presence of WT or HIF-1–deficient myeloid 
cells that reconstitute BM during the first several weeks after 
the transfer. In both control groups, tumor grew progres-
sively during first 4 wk. However, after that mice reconsti-
tuted with HIF-1–deficient BM demonstrated substantial 
delay in tumor growth (P < 0.05; Fig. 7 D). This effect could 
be explained by the reconstitution of lymphoid compartment 
by 7 wk after BM transfer. Adoptive transfer of T cells and 
immunization with specific peptide allowed for bypassing the 
need for lymphoid reconstitution. Immunization of WT 
mice delayed tumor progression in two out of five mice and, 
in one mouse, tumor was rejected (Fig. 7 D). This effect was 
substantially stronger in mice with HIF-1 BM cells. Tumor 
was rejected in two mice and tumor growth was inhibited in 
the remaining three mice (Fig. 7 D).
DISCUSSION
In this study, we evaluated the nature of tumor-associated 
MDSC by comparing the phenotype and function of MDSC 
isolated from spleen and tumor sites from the same mice. It is 
known  that  MDSC  can  differentiate  into  M  and  DC 
(Kusmartsev and Gabrilovich, 2003, 2005). Therefore, it was 
important to assure that we are indeed comparing cells with 
the same phenotype. We sorted MDSC based on the expres-
sion of Gr-1 and CD11b, two markers which are considered 
hallmarks of MDSC. MDSCs from the tumor site and spleen 
had similar morphology and phenotype. Expression of the 
macrophage cell marker F4/80 was slightly higher on tumor 
MDSC  than  on  spleen  cells.  However,  such  rather  minor 
phenotypic differences contrasted with profound differences 
in MDSC function. As was reported previously (Corzo et al., 
2009), spleen MDSC contain a high level of ROS and a rela-
tively modest level of NO and arginase I activity (although it 
was  still  elevated  in  comparison  with  Gr-1+CD11b+  cells 
from naive mice). In striking contrast, tumor MDSC had no 
increase in ROS over naive Gr-1+CD11b+ IMC but a very 
high level of NO and arginase I. These biochemical disparities 
translated into fundamental differences in their ability to sup-
press T cells. Tumor MDSCs were not only more potent in-
hibitors of antigen-specific  T cell functions than spleen MDSCs 
but also, in contrast to spleen MDSCs, suppressed nonspecific 
T  cells.  Our  experiments  with  a  direct  transfer  of  spleen 
MDSC to the tumor microenvironment demonstrated that   
4 h was sufficient to cause dramatic changes in MDSC activ-
ity. These experiments also indicate that observed differences 
were indeed specific for the relative MDSC population and 
not caused by possible contamination of M because the 
phenotype of MDSC was not changed within 4 h after trans-
fer (unpublished data). Our recent study has found that in 2450 Hypoxia maintains MDSC in tumor microenvironment | Corzo et al.
peripheral lymphoid organs and in the tumor site. In lym-
phoid organs, MDSCs retain a high level of NOX2 and in-
creased ROS levels. This is associated with a little increase in 
NO production and arginase I activity. As a result, these MD-
SCs  produce  peroxynitrite  and  exert  their  effect  only  via 
close cell–cell contact with activated antigen-specific T cells, 
which induce antigen-specific T cell tolerance. At the same 
time, these MDSCs fail to suppress antigen-nonspecific acti-
vation of T cells. In contrast, at the tumor site, MDSCs, as a 
result of the effect of hypoxia via HIF-1, dramatically up-
regulate expression of inos and argI, which is associated with 
down-regulation of both NOX2 expression and ROS pro-
duction. Because of these changes, MDSCs acquire the ability 
to suppress antigen-nonspecific T cell functions, which con-
tribute to the profound immune suppression observed within 
the tumor microenvironment. In addition, hypoxia via HIF-1 
promotes differentiation of MDSC to immune suppressive 
TAM, which further supports the immune-suppressive net-
work (Fig. S8). Elucidation of this dual role of MDSC may 
not only help to understand the biology of tumor-associated 
immune suppression but also suggest that any therapeutic in-
terventions should take into account the effect of microenvi-
ronment on the function of these cells.
MATERIALS AND METHODS
Mice and tumor models
All experiments with mice were approved by University of South Florida 
Animal Care and Use Committee. C57BL/6 and BALB/c female mice (6–8 wk 
of age) were obtained from the National Cancer Institute. Mice were kept in 
pathogen-free conditions. CD45.1+ congenic mice (B6.SJL-PtrcaPep3b/BoyJ), 
gp91phox/ (B6.129S6-Cybbtm1Din), HIF-1flox/flox (B6.129-Hif1atm3Rsjo/
JE), and Mx1-Cre+/ (C57BL/6J-Tg(Mx1-cre)1Cgn/J) were purchased from 
The Jackson Laboratory. 2C TCR transgenic mice have been described pre-
viously (Nagaraj et al., 2007). EL4 thymoma was obtained from American 
Type Culture Collection. To establish s.c. tumors, 5 × 105 EL-4 tumor cells 
were injected into C57BL/6 mice. This number of cells formed a tumor with 
a 1.5-cm diameter within 2–3 wk of injection. EL-4 ascitic tumor was gener-
ated by injecting 3 × 105 tumor cells i.p. into C57BL/6 mice. To harvest cells 
from ascitic tumors, mice were sacrificed and the peritoneum was washed 
with 10 ml of ice-cold PBS. Cells were then aspirated and placed on ice im-
mediately. The CT26 colon carcinoma model used in some in vitro experi-
ments was established by injecting 5 × 105 CT26 tumor cells s.c. into BALB/c 
mice. The mCC10TAg transgene model of lung cancer was described previ-
ously (Magdaleno et al., 1997).
Patients
14 patients (47–78 yr old) with resectable T3 or T4 and N2b stage of HNC were 
enrolled in the study after signing University of South Florida IRB-approved 
consent. Patients did not receive radiation or chemotherapy for at least 3 mo be-
fore sample collection. Peripheral blood and tumor tissues were collected at the 
time of surgery from all patients. To obtain single cell suspensions from tumors, 
solid tissue was subjected to 1 h of enzymatic digestion using 0.1 mg/ml hyal-
uronidase (Sigma-Aldrich), 2 mg/ml collagenase (Sigma-Aldrich), 600 U/ml 
DNase (Sigma-Aldrich), and 0.2 mg/ml protease (Sigma-Aldrich) in RPMI 
1640. The digested tissue was passed through a 70-µm mesh, and erythrocytes 
were removed by hypotonic lysis and washed thoroughly to remove debris. 
Mononuclear cell suspensions were obtained from whole blood using density 
gradient centrifugation. All cell samples were analyzed within 3 h after collection. 
Cells were loaded with DCFDA. To identify live MDSC, mononuclear cells were 
first labeled with PerCP-Cy5.5–conjugated anti-CD14, APC-conjugated anti-
CD11b, and PE-Cy-7–conjugated anti-CD33. Antibody-labeled cells were then 
finally resuspended in DAPI buffer to identify viable cells before data collection. 
ODD of HIF-1 enables binding of the ubiquitination ligase 
von Hippel-Lindau tumor suppressor protein, which leads to 
degradation of HIF-1 by the proteosome. In contrast, at   
oxygen levels <5%, hydroxylation is inhibited leading to sta-
bilization of HIF-1. HIF-1 has been directly implicated in 
the up-regulation of iNOS (for review see Yang et al., 2002) 
and arginase (Albina and Reichner, 2003; Sica and Bronte, 
2007) in macrophages. HIF-1 has been shown to suppress 
oxidative phosphorylation and ROS production in mitochon-
dria (Kim et al., 2006; Papandreou et al., 2006). Our data 
demonstrated that HIF-1 is directly responsible for conver-
sion of MDSC in the tumor microenvironment to antigen-
nonspecific suppressors of T cell function via up-regulation 
of arginase and NO.
Our data also indicate that hypoxia, primarily via HIF-1, 
has a direct effect on MDSC differentiation. 2 d after adoptive 
transfer, >60% of MDSC in the spleen retained an immature 
phenotype, whereas the rest of the cells differentiated evenly 
into M and DCs. In contrast, MDSC transferred into tumor 
site differentiated much more rapidly, with most of the cells 
acquiring the phenotype of M. Experiments with MDSC 
culture  in  hypoxic  conditions  recapitulated  these  findings. 
Stabilization of HIF-1 with DFO reproduced this effect, 
suggesting that HIF-1 could be an important factor regulating 
the differentiation of MDSC to TAM. MDSC lacking HIF-1 
did not differentiate into TAM within the tumor microenvi-
ronment or hypoxia but instead acquired markers of DCs.
Experiments with vaccination of HIF-1–deficient tumor-
bearing mice support an important role of HIF-1 in anti-
tumor responses. Even without vaccination, mice that received 
HIF-1–deficient BM cells demonstrated a significant delay 
in tumor progression. This effect was observed only 4–5 wk 
after tumor inoculation and could be possibly explained by 
the reconstitution of the lymphoid compartment by that time 
(6–7  wk  after  BM  transfer).  Stronger  antitumor  responses 
were not necessarily the result of improved function of my-
eloid cells because HIF-1 is known to negatively affect the 
function of T cells as well. Deletion of HIF-1 in T cells re-
sulted in their activation in vitro and in vivo (Lukashev et al., 
2006; Thiel et al., 2007). However, experiments with adoptive 
transfer of antigen-specific Pmel-1 T cells (which are HIF-
1+/+) and vaccination of mice 1 wk after tumor inoculation 
allowed for better interpretation of the results. Our experi-
ments indicated that mice that received HIF-1–deficient 
BM developed stronger antitumor response than mice with 
WT HIF-1 BM. It is important to point out that those ex-
periments,  although  suggestive,  cannot  definitively  address 
the specific effect of HIF-1 deletion in MDSC because lack 
of HIF-1 in other myeloid cells (DC and M) may also im-
pact  antitumor  responses.  More  specific  depletion  experi-
ments will be necessary to clarify this question.
Our study may suggest a model of MDSC differentiation 
and function in cancer. Expansion of IMCs in BM of tumor-
bearing hosts, which is governed in large part by up-regulation 
of  STAT3  (Nefedova  et  al.,  2004;  Cheng  et  al.,  2008;   
Kujawski et al., 2008), results in an accumulation of MDSC in JEM VOL. 207, October 25, 2010 
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qRT-PCR
RNA  was  extracted  with  Trizol  (Invitrogen).  cDNA  was  synthesized 
and used for the evaluation of gene expression as described previously   
(Nefedova et al., 2007). To detect arg1, inos, gp91phox, and p47phox, PCR 
was  performed  with  2  µl  cDNA,  TaqMan  Universal  PCR  Master  Mix 
(Applied  Biosystems),  and  target  gene  assay  mix  containing  sequence- 
specific  primers  and  6-carboxyfluorescein  dye–labeled  TaqMan  minor 
groove  binder  probe  (Applied  Biosystems).  Amplification  with  18S  en-
dogenous control assay mix was used for controls. PCR was performed in 
triplicate for each sample. Data quantitation was performed using the rela-
tive standard curve method. Expression levels of the genes were normalized 
by 18S mRNA. To detect expression of cytokines and -actin, PCR was 
performed with 12.5 µl SYBR Master Mixture (Applied Biosystems) and 
the following primers: sense+ IL-6, 5-ATCCAGTTGCCTTCTTGGG-
ACTGA-3; IL-12, 5-ATGCAGCAAGTGGGCATGTGTT-3; TGF-,   
5-TACGTCAGACATTCCGGGAAGCAGT-3; IL-10, 5-TACCAAA-
GCCACAAAGCAGCCT-3; and -actin, 5-ACCGCTCGTTGCCAATA-
GTGATGA-3. The expression of IL-6, TGF-, IL-12, and IL-10 were 
normalized to -actin.
Western blotting
Cells were lysed in TNE buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
and 1 mM EDTA) containing 1% NP-40 in the presence of protease and 
phosphatase inhibitors. Whole-cell lysates were subjected to 8% SDS-PAGE 
and transferred to PVDF membranes. Membranes were probed with appro-
priate primary antibodies overnight at 4°C. Membranes were washed and in-
cubated overnight at 4°C with secondary antibody conjugated with peroxidase. 
Results were visualized by chemiluminescence detection using a commercial 
kit (GE Healthcare). To confirm equal loading, membranes were stripped and 
reprobed with antibody against -actin (Santa Cruz Biotechnology, Inc.)
Evaluation of T cell function
Proliferation. Splenocytes from 2C transgenic mice, depleted of red cells, 
were placed in triplicates into U-bottom 96-well plates (2 × 105/well). For 
antigen-specific responses, splenocytes were cultured in the presence of cog-
nate antigen (2C-specific peptide SIYRYYGL) and cultured for 72 h. For 
anti-CD3/CD28 antibody-induced T cell proliferation, splenocytes were 
cultured in the presence of 1 µg/ml anti-CD3 antibody and 5 µg/ml anti-
CD28 antibody. 18 h before harvesting, cells were pulsed with 3H-thymidine 
(1 µCi/well; GE Healthcare). 3H-thymidine uptake was counted using a liq-
uid scintillation counter and expressed as cpm.
IFN- production. The number of IFN-–producing cells in response to 
cognate antigens or CD3/CD28 antibodies were evaluated in an ELISPOT 
assay as previously described (Nagaraj et al., 2007). Each well contained 105 
splenocytes. The number of spots was counted in triplicates and calculated 
by an automatic ELISPOT counter (Cellular Technology).
Treatment of tumor-bearing mice
Mice were inoculated s.c. with 3 × 105 B16 tumor cells, and 6 d later the 
mice received 3 × 106 splenocytes from Pmel-1 T cell receptor transgenic 
mice. 1 d later, the mice were immunized with 200 µg Hugp10025-33 peptide 
(KVPRNQDWL) mixed with 2 toll-like receptor agonists (50 µg poly-IC 
and 100 µg CpG-1826). Poly-IC (Hiltonol, a clinical grade stabilized formu-
lation containing poly-l-lysine and carboxymethyl cellulose) was provided 
by A. Salazar (Oncovir, Inc., Washington, DC). CpG-1826 was prepared by 
the Mayo Clinic Molecular Core Facility. Tumor growth was monitored   
every 3–4 d in individually tagged mice by measuring two opposing diame-
ters with a set of calipers.
Evaluation of the presence of myeloid cells in the areas of hypoxia 
in tumor
To detect hypoxia, we used pimonidazole HCl, which is activated in hy-
poxic cells and forms stable covalent adducts with thiol groups in proteins, 
peptides, and amino acids. The antibody reagent binds to these adducts, allowing 
To detect iNOS in MDSCs after surface staining with PerCP-Cy5.5–conjugated 
anti-CD14, APC-conjugated anti-CD11b and PE-Cy-7–conjugated anti-CD33 
antibodies were fixed, permeabilized using the Cytofix/Cytoperm Fixation/
Permeabilization kit (BD), and analyzed using an LSR II flow cytometer (BD). 
At least 100,000 cells were collected for each parameter to obtain reliable data. 
Analysis of the samples was performed essentially as described elsewhere (Mirza 
et al., 2006).
Cell isolation
To collect splenocytes, single cell suspensions were prepared from spleens, 
and red cells were removed using ammonium chloride lysis buffer. MDSCs 
were isolated by cell sorting on a FACSAria (BD) after cell staining with 
APC-conjugated anti–Gr-1 antibody and PE-conjugated anti-CD11b anti-
bodies. To harvest peritoneal macrophages, mice were injected i.p. with   
1 ml thioglycollate (BD). 3 d later, peritoneal cells were obtained by perito-
neal lavage with 10 ml of ice-cold PBS. Peritoneal macrophages were har-
vested using magnetic beads and biotinylated anti-F4/80 antibody.
Reagents
Arginase inhibitor NW-hydroxyl-nor-l-arginine (nor-NOHA) and iNOS 
inhibitor  NG-monomethyl-l-arginine  (L-NMMA)  were  obtained  from 
EMD. 2C-specific (H-2Kb, SIYRYYGL) and control (H-2Kb RAHYNIVTF) 
peptides were obtained from American Peptide Company. DCFDA was 
purchased from Invitrogen. Antibodies against p47phox were purchased from 
Santa Cruz Biotechnology, Inc., anti–HIF-1 antibody from R&D Systems, 
and biotinylated anti-F4/80 antibody from AbD Serotec. All other antibod-
ies used for flow cytometry were purchased from BD.
MDSC isolation from solid tumors
Tumors were dissected and digested with 0.7 mg/ml collagenase XI (Sigma-
Aldrich) and 30 mg/ml of type IV bovine pancreatic DNase (Sigma-Aldrich) 
for 45 min at 37°C. Remaining red cells were lysed by ACK and dead cells 
were removed by centrifugation with Lympholyte M. Gr-1+ cells were iso-
lated by using biotinylated anti–Gr-1 antibody and streptavidin microbeads 
with MiniMACS columns (Miltenyi Biotec).
Cell culture and hypoxic conditions
MDSCs  were  cultured  in  complete  RPMI  media  containing  10  ng/ml   
GM-CSF. A hypoxic environment (1% O2 with 5% CO2) was created and 
maintained using a C-Chamber Hypoxic Incubator Chamber (BioSpherix).
ROS detection, arginase activity and NO production
The oxidation-sensitive dye DCFDA was used to measure ROS production 
by MDSC. Cells were incubated at 37°C in RPMI in the presence of   
2.5 µM DCFDA for 30 min. For PMA-induced activation, cells were simul-
taneously  cultured,  along  with  DCFDA,  with  30  ng/ml  PMA  (Sigma- 
Aldrich). Cells were then labeled with anti–Gr-1 and anti-CD11b antibodies 
on ice and evaluated by flow cytometry.
Arginase  activity  was  measured  in  cell  lysates,  as  previously  described 
(Kusmartsev and Gabrilovich, 2005). In brief, cells were lysed for 30 min with 
0.1% Triton X-100. To 100 µl of protein lysate (25 µg/ml), 100 µl of 25 mM Tris-
HCl and 10 µl of 10 mM MnCl2 were added, and the enzyme was activated by 
heating for 10 min at 56°C. Arginine hydrolysis was conducted by incubating the 
lysate with 100 µl of 0.5 M L-arginine, pH 9.7, at 37°C for 120 min. The reaction 
was stopped with 900 µl H2SO4 (96%)/H3PO4 (85%)/H2O (1/3/7, vol/vol/vol). 
The urea concentration was measured at 540 nm after addition of 40 µl 
-isonitrosopropiophenone (dissolved in 100% ethanol), followed by heating 
at 95°C for 30 min. One unit of enzyme activity is defined as the amount of 
enzyme that catalyzed the formation of 1 µmol urea per min.
To detect nitrites, equal volumes of culture supernatants (100 µl) were 
mixed with Greiss reagent. After a 10-min incubation at room temperature, the 
absorbance at 550 nm was measured using a microplate plate reader (Bio-Rad 
Laboratories). Nitrite concentrations were determined by comparing the absor-
bance values for the test samples to a standard curve generated by serial dilution 
of 0.25 mM sodium nitrite.2452 Hypoxia maintains MDSC in tumor microenvironment | Corzo et al.
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